CVS Health (CVS) Delivers Strong Q2 Results with +42.5% Adjusted EPS Growth
Key Takeaways
- Adjusted EPS (Earnings Per Share) of $2.58 crushed the Wall Street consensus estimate of roughly $1.83–$1.87, representing a beat of approximately 38–41%.
- Total revenue reached $106.1 billion, up 7.3% year-over-year and well above the analyst forecast of around $100 billion.
- Net income nearly tripled to approximately $3.0 billion compared to $1.0 billion in the prior-year quarter, while adjusted operating income surged 35% to $5.2 billion.
- All three operating segments — Health Care Benefits (Aetna), Health Services (Caremark), and Pharmacy & Consumer Wellness — posted year-over-year earnings growth.
- Full-year 2026 guidance was raised significantly, with adjusted EPS now seen at $7.90–$8.10, up $0.60 from the prior range, and cash flow from operations lifted to at least $11.5 billion.
- Shares fell approximately 7–9% in premarket trading despite the blowout quarter, as management flagged 2027 headwinds tied to the 340B drug discount program and Caremark membership trends.
Why This Quarter Matters
CVS Health entered earnings season on solid footing. The stock had risen roughly 39% over the previous quarter, supported by a first-quarter beat, better margins at the Aetna health insurance unit, and growing confidence in the company’s multi-year turnaround. With shares near a 52-week high of $110.68, expectations were high. The second quarter offered a key check on whether CVS could maintain operational progress across insurance, pharmacy benefit management, and retail pharmacy amid ongoing medical cost pressures and regulatory questions. For investors, the report was not just about one quarter but a signal of management’s ability to meet full-year targets and build sustainable growth.
Strong Results Across the Board
CVS Health posted its best quarter in some time, beating estimates on both revenue and earnings. Total revenue came in at $106.1 billion, up 7.3% from $98.9 billion in the second quarter of 2025 and ahead of the roughly $100 billion consensus. Adjusted EPS reached $2.58, up 42.5% from $1.81 a year earlier and about $0.75 above expectations. On a GAAP basis, diluted EPS was $2.31 versus $0.80 in the prior-year period.
Adjusted operating income increased 35.4% to $5.2 billion, showing strength across segments. The Health Care Benefits segment, led by Aetna, stood out with adjusted operating income jumping more than 85% year-over-year to $2.43 billion thanks to tighter medical cost control and solid Medicare results. The Medical Benefit Ratio improved to 87.4% from 89.9%, a favorable sign for insurance margins.
The Health Services segment, which includes Caremark, generated revenue of $51.8 billion, up 11.5%, with adjusted operating income rising 10% to $1.73 billion. Pharmacy claims processed totaled 473 million on a 30-day equivalent basis. The Pharmacy & Consumer Wellness segment reported revenue of $33.8 billion, essentially flat year-over-year, but adjusted operating income grew 10.2% to $1.48 billion, helped by a 7% rise in same-store prescription volumes and contributions from acquired Rite Aid locations.
Year-to-date cash flow from operations reached $10.6 billion, with about $6.3 billion generated in the second quarter alone—well above $1.9 billion in the same period last year. The company paid nearly $880 million in dividends, extending its 56-year streak of consecutive payments.
Management raised full-year 2026 guidance: adjusted EPS is now projected at $7.90–$8.10 (up from $7.30–$7.50), GAAP EPS at $6.84–$7.04, total revenue of at least $414 billion, and operating cash flow of at least $11.5 billion, a $2 billion increase from prior guidance.
I also checked sector comparables using Tickeron’s AI Screener to see how CVS stacks up against peers on key metrics.
Market Reaction Highlights Forward Concerns
Despite the strong numbers, CVS shares dropped approximately 7–9% in premarket trading, moving from a prior close of $104.42 to around $94–$96. The reaction reflected a gap between solid current results and longer-term worries. Management noted potential 2027 pressures from the 340B drug discount program and lower Caremark membership due to more selective contracting and product exits. For a stock that had climbed nearly 70% over the past twelve months, the cautious outlook prompted some profit-taking even as near-term guidance was lifted.
Looking Ahead: Momentum Versus 2027 Headwinds
Investors will weigh CVS Health’s near-term progress against the challenges flagged for 2027. The company enters the second half of 2026 with several positives: Aetna’s margin recovery is ahead of schedule, prescription volumes are rising, and Rite Aid integration is adding value in the Pharmacy & Consumer Wellness segment.
Key areas to watch include the 340B program, where manufacturer restrictions and a shift of some specialty drugs to generics could affect revenue and margins next year. Management noted that some second-half 2026 value was pulled forward, which may moderate the pace of earnings growth in coming quarters.
On the growth side, CVS is expanding in the GLP-1 medication market with an enhanced direct-to-consumer weight-management offering. MinuteClinic virtual visits are priced at $29 with same-day pharmacy pickup available at more than 9,000 locations. Partnerships with Eli Lilly and Novo Nordisk should help capture additional revenue in this fast-growing category.
CVS is also investing in artificial intelligence and consumer technology, including the Health 100 platform and an AI-powered assistant, to improve efficiency and customer experience. These efforts are part of a longer-term strategy, though their full impact will take time to appear in results. The main question remains whether CVS can sustain its earnings path through 2027 while managing reimbursement pressures, membership changes, and regulatory shifts.
From what I see, the 340B and membership dynamics will be worth monitoring closely in upcoming updates.
Using Tickeron’s AI Screener for Deeper Analysis
In my own research process, I frequently rely on Tickeron’s AI Screener to quickly filter healthcare stocks by operational metrics, technical signals, and AI-driven insights. It helps surface comparable names and post-earnings momentum ideas without spending hours on manual scans, allowing more time to focus on the key drivers behind results like those from CVS Health.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CVS in -2.18% downward trend, sliding for three consecutive days on October 01, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CVS declined for three days, in 171 of 285 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 52 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 27 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
The Aroon Indicator for CVS entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVS's RSI Oscillator exited the oversold zone, 20 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 53 cases where CVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 232 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.410) is slightly lower than the industry average of (3.247). P/E Ratio (23.179) is within average values for comparable stocks, (139.958). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.030) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement